Streetbeat News

Stock Prices

HRB

H&R Block (NYSE:HRB) reported Q3 2024 adjusted EPS from continuing operations of $4.94, surpassing the $4.62 estimate, with sales of $2.184B also beating the $2.137B estimate. This represents a 17.62% increase in earnings and a 4.35% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:07 pm

GEN

Gen Digital (NASDAQ:GEN) reported Q4 earnings of $0.53 per share, surpassing the $0.52 estimate, and sales of $967M, beating the $965.02M estimate. This represents a 15.22% increase in earnings and a 2.11% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:07 pm

PGNY

Progyny forecasts its FY24 adjusted EPS to be between $1.61 and $1.68, significantly higher than the estimated $0.69. However, its revenue projection of $1.230B to $1.270B falls short of the $1.298B estimate.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:06 pm

PGNY

Progyny forecasts an adjusted EPS of $0.39-$0.41 for Q2 2024, surpassing the estimated $0.18. However, its revenue projection of $300M-$310M falls short of the expected $335.760M.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:06 pm

DIOD

Diodes (NASDAQ:DIOD) reported Q1 earnings of $0.28 per share, missing the consensus estimate of $0.31, marking a 82.39% decrease from last year's $1.59 per share. Sales were $301.97M, also below the expected $305.01M, a 35.37% decrease from the previous year's $467.24M.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:06 pm

FATE

Fate Therapeutics (NASDAQ:FATE) reported Q1 2024 GAAP EPS of $(0.47), matching analyst estimates, but with a 147.37% decrease from the previous year. Sales reached $1.925M, surpassing the $1.114M estimate but showing a 96.74% decrease from the previous year's $58.980M.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:05 pm

BLNK

Blink Charging shares are trading higher following the announcement of better-than-expected Q1 results.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:04 pm

COLL

Collegium Pharmaceutical announced that Joe Ciaffoni will resign as President and CEO, effective May 24, 2024. Michael Heffernan, the Board Chairman, will serve as interim President and CEO following Ciaffoni's departure.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:03 pm

PODD

Insulet (NASDAQ:PODD) reported Q1 earnings of $0.73 per share, surpassing the $0.39 estimate, marking an 87.18% beat and a 217.39% increase from last year. Sales reached $441.70M, exceeding the $424.05M estimate by 4.16% and showing a 23.35% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:03 pm

PGNY

Progyny (PGNY) reported Q1 2024 adjusted EPS of $0.39, surpassing the $0.13 estimate, but its sales of $278.078M fell short of the $289.457M forecast. This represents a 7.62% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:03 pm